ES2686545T3 - Método de tratamiento de la inflamación - Google Patents

Método de tratamiento de la inflamación Download PDF

Info

Publication number
ES2686545T3
ES2686545T3 ES11763501.1T ES11763501T ES2686545T3 ES 2686545 T3 ES2686545 T3 ES 2686545T3 ES 11763501 T ES11763501 T ES 11763501T ES 2686545 T3 ES2686545 T3 ES 2686545T3
Authority
ES
Spain
Prior art keywords
sorbent
use according
polymer
styrene
biocompatible polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11763501.1T
Other languages
English (en)
Spanish (es)
Inventor
Phillip P. Chan
Wei-Tai Young
Vincent J. Capponi
Thomas D. Golobish
Robert H. Barlett
Humayra B. ALI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytosorbents Corp
Original Assignee
Cytosorbents Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytosorbents Corp filed Critical Cytosorbents Corp
Application granted granted Critical
Publication of ES2686545T3 publication Critical patent/ES2686545T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A61K31/75—Polymers of hydrocarbons of ethene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
    • B01J20/26—Synthetic macromolecular compounds
    • B01J20/261—Synthetic macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28002—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their physical properties
    • B01J20/28004—Sorbent size or size distribution, e.g. particle size
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
    • B01J20/28069—Pore volume, e.g. total pore volume, mesopore volume, micropore volume
    • B01J20/28073—Pore volume, e.g. total pore volume, mesopore volume, micropore volume being in the range 0.5-1.0 ml/g
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
    • B01J20/28069—Pore volume, e.g. total pore volume, mesopore volume, micropore volume
    • B01J20/28076—Pore volume, e.g. total pore volume, mesopore volume, micropore volume being more than 1.0 ml/g
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/305—Addition of material, later completely removed, e.g. as result of heat treatment, leaching or washing, e.g. for forming pores
    • B01J20/3064—Addition of pore forming agents, e.g. pore inducing or porogenic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F212/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
    • C08F212/34—Monomers containing two or more unsaturated aliphatic radicals
    • C08F212/36—Divinylbenzene
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
    • C08J9/26—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a solid phase from a macromolecular composition or article, e.g. leaching out
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2201/00—Foams characterised by the foaming process
    • C08J2201/04—Foams characterised by the foaming process characterised by the elimination of a liquid or solid component, e.g. precipitation, leaching out, evaporation
    • C08J2201/044—Elimination of an inorganic solid phase
    • C08J2201/0444—Salts
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2207/00—Foams characterised by their intended use
    • C08J2207/10—Medical applications, e.g. biocompatible scaffolds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2325/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring; Derivatives of such polymers
    • C08J2325/02—Homopolymers or copolymers of hydrocarbons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Polymers & Plastics (AREA)
  • Thermal Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Materials Engineering (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES11763501.1T 2010-04-01 2011-04-01 Método de tratamiento de la inflamación Active ES2686545T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31999310P 2010-04-01 2010-04-01
US319993P 2010-04-01
PCT/US2011/030919 WO2011123767A1 (en) 2010-04-01 2011-04-01 Method of treating inflammation

Publications (1)

Publication Number Publication Date
ES2686545T3 true ES2686545T3 (es) 2018-10-18

Family

ID=44712650

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11763501.1T Active ES2686545T3 (es) 2010-04-01 2011-04-01 Método de tratamiento de la inflamación

Country Status (9)

Country Link
US (6) US9717755B2 (https=)
EP (2) EP2552459B1 (https=)
JP (2) JP6073778B2 (https=)
CN (2) CN103037869A (https=)
AU (1) AU2011234978B2 (https=)
CA (1) CA2795177C (https=)
ES (1) ES2686545T3 (https=)
MX (1) MX342421B (https=)
WO (1) WO2011123767A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6073778B2 (ja) * 2010-04-01 2017-02-01 サイトソーベンツ・コーポレーション 炎症を治療する方法
US9861733B2 (en) 2012-03-23 2018-01-09 Nxstage Medical Inc. Peritoneal dialysis systems, devices, and methods
EP2688602B1 (en) 2011-03-23 2019-11-06 NxStage Medical, Inc. Peritoneal dialysis systems, devices, and methods
EP2679302A1 (de) 2012-06-28 2014-01-01 Zentrum für biomedizinische Technologie der Donau- Universität Krems Selektives Sorptionsmittel für die extrakorporale Blutreinigung
AU2013282320B2 (en) * 2012-06-29 2017-10-19 Cytosorbents Corporation Methods of using polymers
US10639405B2 (en) 2014-07-22 2020-05-05 Asahi Kasei Medical Co., Ltd. Adsorbent for removing histone and purification device for liquid derived from living organism
WO2016054458A1 (en) 2014-10-02 2016-04-07 Cytosorbents Corporation Use of gastroinstestinally administered porous enteron sorbent polymers to prevent or treat radiation induced mucositis, esophagitis, enteritis, colitis, and gastrointestinal acute radiation syndrome
RU2018134142A (ru) * 2016-03-08 2020-04-08 Сайтосорбентс Корпорейшн Применение гранулированного сорбента на основе гемосовместимого пористого полимера для удаления молекулярных структур, ассоциированных с патогенами, и молекулярных структур, ассоциированных с повреждениями
RU2018146119A (ru) 2016-05-26 2020-06-26 Сайтосорбентс Корпорейшн Использование гемосовместимого сорбента из пористых полимерных шариков для удаления вызывающих эндотоксикоз молекул
EP3630325A4 (en) * 2017-05-23 2021-02-17 Cytosorbents Corporation METHODS FOR TREATMENT OF TRAUMATIC BRAIN INJURY
WO2018237375A1 (en) 2017-06-24 2018-12-27 Nxstage Medical, Inc. Peritoneal dialysis fluid preparation and/or treatment devices methods and systems
CN111405870A (zh) * 2017-08-31 2020-07-10 西托索尔本茨公司 从体液中降低晚期糖基化终末产物
US20190262526A1 (en) 2018-02-28 2019-08-29 Nxstage Medical, Inc. Fluid Preparation and Treatment Devices Methods and Systems
CN120189436A (zh) * 2018-11-16 2025-06-24 希玛奈克斯特股份有限公司 用于控制炎症患者中不良事件的方法
WO2021034773A1 (en) * 2019-08-16 2021-02-25 Cytosorbents Corporation Methods for improving bone fracture healing
WO2021063708A1 (en) 2019-09-30 2021-04-08 Hemotune Ag Assembly for extracorporeal treatment of body fluids
EP4135749A4 (en) * 2020-04-14 2024-04-17 Cytosorbents Corporation IMPROVED IMMUNE RESPONSE AND REDUCED IMMUNOPARALYSIS WITH IMMUNOMODULATOR TREATMENT
CA3192184A1 (en) * 2020-08-19 2022-02-24 Cytosorbents Corporation Therapeutic and cosmetic wound treatment
CA3237831A1 (en) * 2021-11-29 2023-06-01 Cytosorbents Corporation Improved cancer immunotherapy treatments

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU213165B (en) * 1993-05-11 1997-02-28 Bot Process to prepare biopolymers with detoxicating activity
US6416487B1 (en) 1997-07-30 2002-07-09 Renal Tech International Llc Method of removing beta-2 microglobulin from blood
US5904663A (en) 1997-07-30 1999-05-18 Braverman; Andrew Method of removing beta-2 microglobulin from blood
US20020159995A1 (en) * 1997-07-30 2002-10-31 Renal Tech International Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, generated as a result of extracorporeal blood processing
US20020197250A1 (en) 2001-04-10 2002-12-26 Renal Tech International Biocompatible devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood
EP1044066A1 (en) 1998-01-06 2000-10-18 Cerus Corporation Batch devices for the reduction of compounds from biological compositions containing cells and methods of use
US20020197252A1 (en) 2001-04-10 2002-12-26 Renal Tech International Selective adsorption devices and systems
US7651974B2 (en) * 2002-11-01 2010-01-26 Kureha Chemical Industry Co., Ltd. Adsorbent for oral administration
KR100680449B1 (ko) * 2002-11-01 2007-02-08 가부시키가이샤 쿠레하 경구투여용 흡착제
TWI370012B (en) 2004-04-02 2012-08-11 Kureha Corp Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
WO2005115336A2 (en) * 2004-05-15 2005-12-08 Collegium Pharmaceutical, Inc. Sprayable formulations for the treatment of acute inflammatory skin conditions
AU2005295708A1 (en) * 2004-10-13 2006-04-27 Relypsa, Inc. Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle
US20060078534A1 (en) * 2004-10-13 2006-04-13 Dominique Charmot Toxin binding compositions
EP1865982A1 (en) 2005-04-06 2007-12-19 Bioartificial Gel Technologies Inc. Hydrogel composition for modulation of topical inflammatory response
EP1842545A1 (en) * 2006-04-04 2007-10-10 Marinomed Biotechnologie GmbH Anti-inflammatory polymer
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
US7875182B2 (en) * 2006-11-20 2011-01-25 Cytosorbents, Inc. Size-selective hemoperfusion polymeric adsorbents
US20090130048A1 (en) * 2007-11-19 2009-05-21 Oronsky Bryan Todd Topical Composition for Treating Pain
CN101307149B (zh) 2008-05-30 2011-06-01 珠海健帆生物科技股份有限公司 一种医用吸附剂载体的制备方法
MX2011003569A (es) * 2008-10-02 2011-06-09 Univ Pittsburgh Administracion de un polimero adsorbente para el tratamiento de inflamacion sistemica.
US8923172B2 (en) * 2009-08-24 2014-12-30 Qualcomm Incorporated Deterministic backoff channel access
JP6073778B2 (ja) * 2010-04-01 2017-02-01 サイトソーベンツ・コーポレーション 炎症を治療する方法
US10064406B2 (en) 2011-01-06 2018-09-04 Cytosorbents Corporation Polymeric sorbent for removal of impurities from whole blood and blood products

Also Published As

Publication number Publication date
US9717755B2 (en) 2017-08-01
US20130195792A1 (en) 2013-08-01
JP2013523772A (ja) 2013-06-17
CA2795177A1 (en) 2011-10-06
EP2552459A1 (en) 2013-02-06
JP2016175914A (ja) 2016-10-06
JP6073778B2 (ja) 2017-02-01
US20180311273A1 (en) 2018-11-01
US10946040B2 (en) 2021-03-16
CN103037869A (zh) 2013-04-10
MX342421B (es) 2016-09-28
WO2011123767A1 (en) 2011-10-06
AU2011234978B2 (en) 2016-03-17
EP2552459A4 (en) 2013-12-25
US20160279163A1 (en) 2016-09-29
US11058715B2 (en) 2021-07-13
US10967001B2 (en) 2021-04-06
US10034894B2 (en) 2018-07-31
AU2011234978A1 (en) 2012-10-18
EP2552459B1 (en) 2018-07-18
CA2795177C (en) 2018-07-03
MX2012011305A (es) 2013-01-29
EP3384916A1 (en) 2018-10-10
CN107260755A (zh) 2017-10-20
US20170296574A1 (en) 2017-10-19
US20210330697A1 (en) 2021-10-28
US20190282608A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
ES2686545T3 (es) Método de tratamiento de la inflamación
JP5670336B2 (ja) 全身性炎症の治療のためのポリマー吸着剤の投与
JP6945607B2 (ja) ポリマーの使用法
JP2013523772A5 (https=)
JP2023078459A (ja) 外傷性脳損傷の治療法
JP2020532417A (ja) 体液からの終末糖化産物の削減